Effects of omega-3 fatty acids on arterial stiffness in patients with hypertension: a randomized pilot study. by Krantz, Mori J et al.
UCSF
UC San Francisco Previously Published Works
Title
Effects of omega-3 fatty acids on arterial stiffness in patients with hypertension: a 
randomized pilot study.
Permalink
https://escholarship.org/uc/item/7764w5xn
Journal
Journal of negative results in biomedicine, 14(1)
ISSN
1477-5751
Authors
Krantz, Mori J
Havranek, Edward P
Pereira, Rocio I
et al.
Publication Date
2015-12-02
DOI
10.1186/s12952-015-0040-x
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
BRIEF REPORT Open Access
Effects of omega-3 fatty acids on arterial
stiffness in patients with hypertension: a
randomized pilot study
Mori J. Krantz1,2*, Edward P. Havranek1,2†, Rocio I. Pereira2†, Brenda Beaty3†, Philip S. Mehler2† and Carlin S. Long1,2†
Abstract
Background: Omega–3 fatty acids prevent cardiovascular disease (CVD) events in patients with myocardial infarction
or heart failure. Benefits in patients without overt CVD have not been demonstrated, though most studies did not use
treatment doses (3.36 g) of omega-3 fatty acids. Arterial stiffness measured by pulse wave velocity (PWV) predicts
CVD events independent of standard risk factors. However, no therapy has been shown to reduce PWV in a blood
pressure-independent manner. We assessed the effects of esterified omega–3 fatty acids on PWV and serum markers
of inflammation among patients with hypertension.
Design and methods: We performed a prospective, randomized; double-blinded pilot study of omega-3 fatty acids
among 62 patients in an urban, safety net hospital. Patients received 3.36 g of omega–3 fatty acids vs. matched
placebo daily for 3-months. The principal outcome measure was change in brachial-ankle PWV. Serum inflammatory
markers associated with CVD risk were also assessed.
Results: The majority (71 %) were of Latino ethnicity. After 3-months, mean change in arterial PWV among omega-3
and placebo groups was −97 cm/s vs. −33 cm/s respectively (p = 0.36 for difference, after multivariate adjustment for
baseline age, systolic blood pressure, and serum adiponectin). Non-significant reductions in lipoprotein-associated
phospholipase A2 (LpPLA2) mass and high sensitivity C-reactive protein (hsCRP) relative to placebo were also observed
(p = 0.08, and 0.21, respectively).
Conclusion: High-dose omega-3 fatty acids did not reduce arterial PWV or markers of inflammation among patients
within a Latino-predominant population with hypertension.
Clinical trial registration: NCT00935766, registered July 8 2009.
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Background
The effects of omega-3 fatty acids on cardiovascular disease
(CVD) outcomes have been mixed. Prospective randomized
trials have previously demonstrated reductions in CVD
events among patients with myocardial infarction [1] and
heart failure [2]. However, no benefits have been reported
among patients without documented CVD [3, 4]. It is un-
clear if the relatively low dose (1g) of omega-3 fatty acids
utilized in these trials contributed to the null effect since
the therapeutic dosage for hypertriglyceridemia is ~4 g/day
[5]. Although a randomized controlled CVD outcomes trial
evaluating ~4-g per day of ethyl eicosapentaenoic acid
(EPA) in addition to baseline statin therapy is underway,
results are not expected until 2017 [6].
Pending results of CVD outcome trials, an assessment
of the effects of omega-3 fatty acids on preclinical pre-
dictors of CVD events may be informative. Omega-3
fatty acids reduce inflamation [7], but improvements in
pulse wave velocity (PWV), have not been demonstrated.
This may reflect inadequate dosing or a lower baseline
CVD risk among populations studied. For example, des-
pite 12-months of therapy with 1.8 g of omega-3 fatty
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acids daily, no reduction in arterial stiffness was detected
among overweight but otherwise healthy middle aged
subjects [8], suggesting that both treatment intensity as
well as underlying CVD risk profile may be important
determinants of benefit.
Arterial PWV is an independent predictor of CVD
events among patients with hypertension [9] and is the
gold standard measurement of arterial stiffness [10].
Given our previous observation that PWV was an inde-
pendent predictor of preclinical atherosclerosis [11], we
assessed effect of high-dose (3.36 g) omega-3 fatty acids
on PWV and secondarily high sensitivity C-reactive
protein (hsCRP), lipoprotein-associated phospholipase
A2 (Lp-PLA2), and serum adiponectin.
Methods
We conducted a prospective, randomized placebo-
controlled, double-blind pilot study. Patients received
either 4 omega-3 fatty acids (Lovaza™ Glaxo Smith Kline,
United Kingdom) capsules or identically matched corn-oil
placebo. Each Lovaza capsule includes 465 mg of EPA and
375 mg of docosahexaenoic acid (DHA) for a total daily
dose of 3.36 g. The treatment period was 3-months with
baseline and follow-up measurements performed in the
morning in a fasted state. The Colorado Multiple Insti-
tutional Review Board approved the study and it was
registered with clinicaltrials.gov. All study participants
signed written informed consent.
Subjects were recruited from outpatient primary care
clinics or a preexisting registry of hypertension patients.
This cohort consisted of 177 individuals; the inclusion
and exclusion criteria for this registry have been previ-
ously reported [11]. Eligible patients were ≥18 years of
age, of either Latino or non-Latino White ethnicity and
had at least one other CVD risk factor including diabetes,
dyslipidemia, obesity, chronic kidney disease, microalbu-
minuria, current smoking, or age >55 for men or >65 for
women, but were excluded if they had pre-existing CVD.
Arterial PWV measurements were performed in the
recumbent position. Supine blood pressure was mea-
sured in duplicate in the non-dominant arm. Bilateral
brachial-ankle PWV was derived from the pulse transit
time between and the estimated path length between
proximal and distal arterial sites expressed as cm/s. In-
flammatory markers and adiponectin were also assessed
while fasting. We chose hsCRP because it has incremental
CVD risk discrimination beyond standard Framingham
risk factors [12] and Lp-PLA2 given its specificity for
inflammation localized to atherosclerotic plaque [13].
Statistical analysis
Means, standard deviations, and medians were calcu-
lated for all continuous variables. For univariate analyses,
comparisons were made using analysis of variance, chi-
squared or Wilcoxon rank sum tests. For change over
time analyses, mixed-effects models were used to account
for repeated measures within participants. Univariate asso-
ciations between baseline risk markers and change in
PWV were assessed, and multivariate models were fitted
to assess for predictors of change. Sensitivity analyses were
performed to assess changes in outcomes among the fol-
lowing subgroups: patients naïve to statin therapy, those
with baseline systolic blood pressure ≥ 140 mm Hg, and
diabetic patients, P-values <0.05 were considered statisti-
cally significant. SAS Version 9.4 (Cary, NC) was used for
all statistical analyses.
Results
Baseline characteristics of the 62 participants are shown
in Table 1 and were consistent with a safety-net popula-
tion. The majority of patients were receiving medication
for chronic hypertension and half had diabetes. Overall,
baseline characteristics were well matched; specifically,
PWV values did not differ by randomization group.
Among baseline variables, older age, higher systolic blood
pressure, and adiponectin were significantly associated
with increased PWV: 16 cm/s increase in mean PWV per
year of increasing age (p < .0001), 7.3 cm/s increase in
mean PWV per each mm Hg of higher systolic blood
pressure (p = 0.005), and 14 cm/s per unit of adiponectin
(p = 0.008).
Changes in risk factors, inflammatory markers, and PWV
are shown in Table 2. Comparative percentage change in
Lp-PLA2 mass, PWV, and hsCRP were all directionally
more favorable in the omega-3 arm but did not achieve
statistical significance (Fig. 1). Absolute change in mean
PWV was −97 cm/s in the omega-3 arm compared
to −33 cm/s in the placebo group (p = 0.36). Reductions
were also seen in mean hsCRP (−0.9 mg/L vs. 0.9 mg/L
in placebo group) and Lp-PLA2 mass (−18.1 ng/mL vs.
−6.1 ng/mL). Numeric mean reductions in risk markers
were relatively larger within subgroups: Among 34 sta-
tin-naïve subjects, the difference in arterial PWV was lar-
ger (−82 vs. +50 cm/s), but remained non-significant
(p = 0.20), though the reduction in mean hsCRP (− 0.8
vs. +1.6 mg/dl) achieved significance (p = 0.03). Among
31 diabetic subjects, PWV (−100 vs. −18 cm/s), hsCRP
(−0.8 vs. +1.7 mg/L), and LpPLA-2 mass (−11.1 vs.
−4.1 ng/ml) were non-significantly lower with active
treatment (minimal p-value 0.19). Among 24 subjects
with baseline systolic blood pressure ≥ 140 mm Hg PWV
(−98 vs. −65 cm/s), hsCRP (−1.0 vs. +0.8 mg/L), and
LpPLA-2 mass (−32.7 vs. −3.2 ng/ml) were non-
significantly lower with active treatment (minimal p-
value 0.09).
In multivariate analysis accounting for baseline age,
systolic blood pressure and adiponectin, no significant
change in mean PWV [parameter estimate (standard
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error) = -22 (24), p = 0.36] was observed. In analysis in-
cluding only time and treatment group, the reductions
in hsCRP and Lp-PLA2 mass were numerically greater
with omega-3 therapy, but were not statistically significant
(p = 0.08, and 0.21, respectively).
Discussion
To our knowledge, this is the first prospective randomized
trial evaluating the effects of prescription doses of omega-3
fatty acids on arterial stiffness in a Latino-predominant
population. Short-term treatment with omega-3 fatty acids
was not associated with a significant reduction in arterial
PWV. Moreover, with the exception of a reduction in
serum hsCRP among statin-naïve subjects, no significant
improvements in markers of vascular inflammation were
Table 1 Baseline sociodemographic and clinical characteristics
Placebo (N = 35)
N (%) or Mean (SD)
Omega-3 (N = 27)
N (%) or Mean (SD)
Overall (N = 62)
N (%) or Mean (SD)
Age (years) 60.2 (10.8) 62.3 (9.7) 61.1 (10.3)
Female Gender 22 (63 %) 18 (67 %) 40 (65 %)
Race/ethnicity Non-Latino White 7 (20 %) 11 (41 %) 18 (29 %)
Latino 28 (80 %) 16 (59 %) 44 (71 %)
Educational Status Did Not Complete High School 18 (51 %) 10 (37 %) 28 (45 %)
Completed High School 9 (26 %) 10 (37 %) 19 (31 %)
Completed College 8 (23 %) 7 (26 %) 15 (24 %)
Unemployed 28 (80 %) 21 (81 %) 49 (80 %)
Body Mass Index (kg/m2) 31.5 (7.1) 33.9 (8.6) 32.6 (7.8)
Systolic Blood Pressure (mm Hg)a 137 (16) 128 (14) 133 (16)
Diastolic Blood Pressure (mm Hg) 82 (9) 78 (10) 81 (10)
Antihypertensive Medication 32 (91 %) 21 (78 %) 53 (85 %)
Statin therapy 17 (49 %) 11 (41 %) 28 (45 %)
Total cholesterol (mg/dL) 179 (43) 179 (38) 179 (40)
Triglycerides (mg/dL) 188 (103) 173 (65) 182 (89)
HDL-C (mg/dL) 48.4 (14.9) 44.9 (12.4) 46.9 (13.9)
LDL-C (mg/dL) 97 (38) 99 (29) 98 (34)
Diabetes diagnosis 19 (54 %) 12 (48 %) 31 (52 %)
Hemoglobin A1c (%) 6.7 (1.8) 6.3 (1.3) 6.6 (1.6)
Glucose (mg/dL) 127 (61) 111 (25) 120 (49)
Smoking status Current 12 (34 %) 6 (22 %) 18 (29 %)
Former 23 (66 %) 21 (78 %) 44 (71 %)
hsCRP (mg/L) 3.42 (3.35) 5.63 (5.05) 4.38 (4.29)
Adiponectin (ug/mL) 10.6 (8.3) 12.2 (7.8) 11.4 (8.1)
LpPLA2 mass (ng/mL) 244 (46) 252 (62) 247 (53)
Mean PWV (cm/s) 1690 (335) 1602 (324) 1652 (330)
PWV pulse wave velocity, CRP C-reactive protein, Lp-PLA2 lipoprotein-associated phospholipase A2
aSystolic Blood Pressure difference between groups at p < 0.05 using Wilcoxon rank sum test
Table 2 Change in risk marker values from baseline to 3-months
Placebo (N = 35)
Mean (SD)
Omega-3 (N = 27)
Mean (SD)
Pulse Wave Velocity (cm/s) −33 (306) −97 (182)
Total cholesterol (mg/dL) −6.6 (30.4) −0.8 (18.1)
Triglycerides (mg/dL) −30.0 (58.1) −17.6 (45.6)
HDL-C (mg/dL) 0.2 (8.5) 2.9 (14.6)
LDL-C (mg/dL) −2.8 (28.6) 0.7 (18.3)
Hemoglobin A1c (%) −0.13 (0.94) 0.06 (0.44)
Glucose (mg/dL) −13.1 (44.0) 0.6 (23.0)
hsCRP (mg/L) 0.9 (4.4) −0.9 (3.1)
Adiponectin (ug/mL) 0.3 (3.4) −0.4 (2.4)
LpPLA2 mass (ng/mL) −6.1 (31.7) −18.1 (41.1)
CRP C-reactive protein, Lp-PLA2 lipoprotein-associated phospholipase A2
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observed despite a high prevalence of obesity and dia-
betes. Given an association between the metabolic
syndrome and increased arterial stiffness [14], a posi-
tive effect of omega-3 fatty acids might have been
expected.
A number of possible explanations for our findings
merit consideration. One potentially important factor
is the dose of omega-3 utilized. In one study, PWV
was assessed among overweight patients receiving 2,
4, and 6-g of omega-3 fatty acids daily [15]. Reduc-
tions in PWV were observed only in the group re-
ceiving 6-g per day. It is possible that despite the
3.36 g dose in the current study, it was still inad-
equate to reduce PWV, particularly if compliance was
sub-optimal. Although no medication diary or formal-
ized drug reconciliation process was utilized in our study,
this is plausible given the absence of a significant triglycer-
ide reduction observed in the active treatment arm, which
may reflect medication non-adherence in our vulnerable
population. Also, half of the patients in our study were
already receiving statin therapy, which could limit our
ability to further discern a treatment effect. In support of
this possibility, a recent trial among patients with per-
ipheral arterial disease already receiving statin therapy,
found no improvement in PWV after omega-3 fatty
acid treatment [16]. Our findings are in line with this
possibility since the difference in PWV over time be-
tween the groups was larger among statin-naïve sub-
jects. Analogously, an expected greater reduction in
hsCRP was seen among statin-naïve subjects. One fur-
ther study limitation is that fatty acid bioavailability
data were not evaluated, so we don’t know if there was
a relationship between plasma fatty acid level and
changes in PWV.
Another potential explanation for the findings in the
current study is the relatively small sample size. Root
and colleagues also found no reduction in PWV with
omega-3 therapy in a short-term study of 57 patients
[17]. In assessing sample size, approximately 100 subjects
would provide > 80 % power to detect a 10 % decrease in
Fig. 1 Mean change in arterial pulse wave velocity (PWV) from baseline to 3-months based on randomized treatment assignment
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PWV (standard deviation [SD] 350 cm/s) assuming a
baseline PWV of 1700 cm/s. With 62 randomized pa-
tients, the current study had just over 60 % power under
those assumptions. Although the numeric effect size in
the current trial was consistent with this reduction, and
the standard deviation was within assumed range, the
placebo-corrected absolute reduction in PWV was only
4 %. The clinical significance of this numeric finding may
be gleaned from a meta-analysis of observational data
from 17,635 subjects, where a 10 % increase in PWV was
associated with a hazard ratio for CVD events of 1.07
(95 % CI: 1.02 to 1.12) [18].
In addition, the relatively short duration of therapeutic
exposure, may have limited our ability to detect alter-
ations in vascular stiffness. There was also a numeric im-
balance of subjects between arms, which likely reflects a
chance finding in the randomization sequence given the
small sample size. This theoretically may have made a
Type II error more likely. Most importantly, however, no
pharmacologic therapy to date has been shown to re-
duce PWV independent of blood pressure reductions,
suggesting the possibility that any salutatory effects of
omega-3 treatment on inflammation and plaque may be
inadequate to alter vessel wall physiology.
Conclusions
In conclusion, high-dose purified omega-3 fatty acids did
not significantly improve arterial stiffness among hyper-
tensive patients extending the negative results of previous
studies. Given the absence of benefits of omega-3 fatty
acids on CVD events in large randomized controlled clin-
ical trials, this therapy cannot be uniformly recommended
in primary prevention patients despite widespread use.
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